These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 493374)

  • 21. Perspectives. Hitting the FDA ... again.
    Wiener JO
    Faulkner Grays Med Health; 1990 Oct; 44(41):suppl 4 p.. PubMed ID: 10107287
    [No Abstract]   [Full Text] [Related]  

  • 22. Knowledge is power: legislative control of drug industry trade secrets.
    O'Reilly JT
    Spec Law Dig Health Care (Mon); 1987 May; 8(15):7-31. PubMed ID: 10281981
    [No Abstract]   [Full Text] [Related]  

  • 23. "Genericgate".
    Marshall WJ
    Ohio Med; 1989 Nov; 85(11):831-2. PubMed ID: 2601929
    [No Abstract]   [Full Text] [Related]  

  • 24. Plugs for drugs.
    Masson A; Rubin PH
    Regulation; 1986; 10(1):37-43, 53. PubMed ID: 10280556
    [No Abstract]   [Full Text] [Related]  

  • 25. Identity of interferon-beta1a product in multiple sclerosis study.
    Wolf WW
    Ann Neurol; 1997 Apr; 41(4):560. PubMed ID: 9124816
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug product selection legislation: a comparative analysis.
    Wetherbee H; Sharpe TR
    Am J Pharm Sci Support Public Health; 1978; 150(6):171-6. PubMed ID: 576098
    [No Abstract]   [Full Text] [Related]  

  • 27. Generic drug scandals raise questions about safety. FDA reorganizes to increase surveillance, prevent fraud.
    Martin S
    Am Pharm; 1989 Oct; NS29(10):23-4. PubMed ID: 2816714
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of generics will mean cost savings.
    Nelson G
    Internist; 1979 May; 20(4):6-8. PubMed ID: 10242132
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacy compounding of bioidentical hormone replacement therapy (BHRT): a proposed new approach to justify FDA regulation of these prescription drugs.
    Patsner B
    Food Drug Law J; 2008; 63(2):459-91. PubMed ID: 18561473
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA position on product selection for 'narrow therapeutic index' drugs.
    Am J Health Syst Pharm; 1997 Jul; 54(14):1630-2. PubMed ID: 9248609
    [No Abstract]   [Full Text] [Related]  

  • 31. Keeping prescription drugs safe and effective.
    Bryan PA
    Am Fam Physician; 1974 Nov; 10(5):189-93. PubMed ID: 4421343
    [No Abstract]   [Full Text] [Related]  

  • 32. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generic drug substitution.
    Rogowski A; Lemay V
    Med Health R I; 2001 Jul; 84(7):241-4. PubMed ID: 11482281
    [No Abstract]   [Full Text] [Related]  

  • 35. States moving to allow generic substitution.
    Internist; 1979 May; 20(4):12-3. PubMed ID: 10242129
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing the nation's biosimilars program.
    Kozlowski S; Woodcock J; Midthun K; Sherman RB
    N Engl J Med; 2011 Aug; 365(5):385-8. PubMed ID: 21812668
    [No Abstract]   [Full Text] [Related]  

  • 38. Prescriptions enter the political arena.
    Regier H
    J Leg Med (N Y); 1974; 2(2):24-30. PubMed ID: 4545342
    [No Abstract]   [Full Text] [Related]  

  • 39. More states adopt generic substitution laws.
    Goldsmith LS
    J Leg Med (N Y); 1977 Oct; 5(10):31-2. PubMed ID: 303272
    [No Abstract]   [Full Text] [Related]  

  • 40. Bioavailability and bioequivalence requirements: abbreviated applications. Final Rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(244):77668-75. PubMed ID: 12492102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.